A new study found no survival advantage with filgrastim-mobilized peripheral blood stem cells compared to bone marrow transplants from unrelated donors. PBSC transplants are associated with higher rates of chronic graft-versus-host disease (GVHD), particularly in patients receiving unrelated donor transplants.
Researchers have discovered that administering aspirin after standard therapy for venous thromboembolism (VTE) may prevent the recurrence of potentially deadly blood clots. The WARFASA study found that low-dose aspirin reduced VTE recurrence by 6.6% compared to placebo, with a similar incidence of major and non-major bleeding.
Researchers at St. Jude Children's Research Hospital and University College London have achieved early success with a gene therapy developed to treat hemophilia B. The treatment increased Factor IX levels in adults with the disorder, reducing the need for clotting factor injections to prevent bleeding episodes.
Researchers from UH Seidman Cancer Center presented groundbreaking research on autophagy and its potential as a novel therapeutic target for lymphoma and other lymphoid neoplasia. The study showed that targeting autophagy may enhance glucocorticoids' effectiveness in killing cancer cells, offering new hope for cancer treatment.
A Phase III clinical trial found that adding gemtuzumab ozogamicin to standard chemotherapy improved event-free and overall survival in newly-diagnosed acute myeloid leukemia patients aged 50-70. The treatment also reduced toxicity while providing therapeutic benefits.